AAV2-GDNF for Moderate Parkinson's Disease

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

Recruiting Phase 2 Interventional Study
Parkinson Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
45 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
127 (estimated)
Sponsor
AskBio Inc · Industry
Who this trial is looking for

This trial is looking for adults aged 45-75 with moderate Parkinson's disease. Participants will receive a treatment involving a surgical procedure and will be monitored for safety and effectiveness.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 45 and 75 years old.
  • I have been diagnosed with Parkinson's disease in the past 4-10 years.
  • I experience slowness of movement and at least one other symptom.
  • I have motor fluctuations as measured by a diary.
  • I have been stable on my anti-parkinsonian medications for at least 4 weeks.
  • I respond to levodopa therapy.

You may not be able to join if

  • I have a medical, genetic, or neurological condition that may explain my symptoms.
  • I have significant heart or blood vessel problems.
  • I have significant cognitive issues or severe depression/anxiety.
  • I have a history of psychosis or impulse control disorders.
  • I have had cancer, except for treated skin cancers.
  • I have conditions that could affect my safety during surgery.
  • I cannot have an MRI or use gadolinium contrast agents.
  • I have had brain surgery before.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Age 1. Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent Type of Subject and Disease Characteristics 2. Diagnosed with Parkinson's disease in the past 4-10 years (inclusive) as defined by the following: 1. Presence of bradykines…
Contacts

Nisha Chhabria, MD

919-388-1040

askfirst@askbio.com

CONTACT

Gayathri Palety, MD

919-388-1040

askfirst@askbio.com

CONTACT